PRESS RELEASES
Read the latest updates and announcements from ITF Therapeutics.
ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT™ (givinostat) for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference
March 17, 2025 - ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today announced the presentation of seven abstracts at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference being held March 16-19, 2025, in Dallas, Texas. Read More
ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts
March 5, 2025 - ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today announced the opening of the company’s new U.S. headquarters in Concord, Massachusetts. The 10,000-square-foot facility located at 575 Virginia Road, Unit 201, will include corporate offices as well as meeting spaces where ITF will welcome members of the Duchenne muscular dystrophy (DMD) and other rare disease communities. Read More
ITF Therapeutics LLC Announces Multiple Data Presentations at 2025 MDA Clinical and Scientific Conference
February 20, 2025 – ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today announced that seven abstracts have been accepted as poster presentations at the
Muscular Dystrophy Association (MDA) Clinical and Scientific Conference to be held March 16-19, 2025, in Dallas, Texas. Read More
ITF Therapeutics LLC Announces Appointment of Erica L. Monaco, CPA, as Chief Operating Officer
December 4, 2024 - ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today announced the appointment of Erica L. Monaco, CPA, as chief operating officer. Bringing nearly two decades of experience in the pharmaceutical and financial sectors,
Erica will oversee a broad range of strategic and operational functions. Read More
ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy
July 25, 2024 - ITF Therapeutics LLC, the U.S.-based rare disease commercial arm of Italfarmaco, today announced the U.S. commercial launch of
DUVYZAT™ (givinostat), a histone deacetylase inhibitor, for the treatment of patients six years of age and older with Duchenne muscular dystrophy (DMD). Read More
ITF Therapeutics LLC anuncia la disponibilidad comercial de DUVYZAT™ (givinostat) en los EE. UU. para el tratamiento de pacientes con distrofia muscular de Duchenne
25 de Julio de 2024 - ITF Therapeutics LLC, el grupo comercial de enfermedades raras con sede en los EE. UU. de Italfarmaco, anunció hoy el lanzamiento comercial en los EE. UU. de DUVYZAT™ (givinostat), un inhibidor de la histona deacetilasa, para el tratamiento de pacientes con seis años de edad o más que tienen distrofia muscular de Duchenne (DMD). Read More
Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in Duchenne Muscular Dystrophy
March 22, 2024 - Italfarmaco S.p.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Duvyzat™ (givinostat), a novel histone deacetylase (HDAC) inhibitor, for the treatment of patients 6 years or older with Duchenne muscular dystrophy (DMD), a rare X-linked progressive and life-limiting neuromuscular condition with symptoms from early childhood. Read More
Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of Givinostat in Duchenne Muscular Dystrophy (DMD) Published in The Lancet Neurology
March 19, 2024 - Italfarmaco S.p.A. announced today that the full results from the Company’s pivotal phase 3 EPIDYS clinical trial with givinostat in ambulant boys 6 years of age and older with Duchenne muscular dystrophy (DMD) have been published in The Lancet Neurology. Read More
USA
Media inquiries: Brian Connor | +1 212 253 8881 | bconnor@cglife.com
Other inquiries: Patient Advocacy and Communications Lead USA | c.allen@itftherapeutics.com
Global
Media inquiries: Charlotte Spitz or Jacob Verghese | +49 (0)151 7441 6179 | italfarmaco@trophic.eu
Other inquiries: Patient Advocacy and Communications Lead | s.parker@italfarmacogroup.com
